Literature DB >> 8975910

Activation of intestinal intraepithelial T lymphocytes in calves infected with Cryptosporidium parvum.

C R Wyatt1, E J Brackett, L E Perryman, A C Rice-Ficht, W C Brown, K I O'Rourke.   

Abstract

The objective of this study was to identify disease-related changes in lymphocyte populations within ileal mucosae of calves with cryptosporidiosis. Groups of five neonatal calves were orally infected at 3 days of age with 10(8) oocysts and maintained in enteric-pathogen-free conditions until clinical disease was established or until the animals had recovered from disease. Age-matched uninfected calves were used for comparison. Ileal mucosal lymphocytes were collected, quantitated, and phenotyped to determine whether changes in lymphocyte composition occurred in infected animals. We observed significantly larger numbers of intraepithelial CD8+ T lymphocytes in ileal mucosae from acutely infected calves compared with those from control animals. In addition, a proportion of intraepithelial CD4+ T cells from acutely infected calves coexpressed CD25, whereas there was an absence of coexpressed CD25 on CD4+ T cells from control calves. Ex vivo reverse transcriptase PCR of RNA from intraepithelial lymphocytes from control calves showed a cytokine expression pattern consisting of tumor necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-gamma), while intraepithelial lymphocytes from calves with cryptosporidiosis expressed IFN-gamma but not TNF-alpha. Together, the results indicate that changes occur in the ileal intraepithelial lymphocyte population coincidently with Cryptosporidium parvum-induced enteric disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8975910      PMCID: PMC174574          DOI: 10.1128/iai.65.1.185-190.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Cloning, sequence, and expression of bovine interferon-gamma.

Authors:  D P Cerretti; K McKereghan; A Larsen; D Cosman; S Gillis; P E Baker
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

Review 2.  Cryptosporidium spp. and cryptosporidiosis.

Authors:  R Fayer; B L Ungar
Journal:  Microbiol Rev       Date:  1986-12

3.  Cloning and characterization of the tandemly arranged bovine lymphotoxin and tumour necrosis factor-alpha genes.

Authors:  I Cludts; Y Cleuter; R Kettmann; A Burny; L Droogmans
Journal:  Cytokine       Date:  1993-07       Impact factor: 3.861

4.  Reactivity of workshop antibodies on L cell and COS cell transfectants expressing bovine CD antigens.

Authors:  N D MacHugh; E L Taracha; P G Toye
Journal:  Vet Immunol Immunopathol       Date:  1993-11       Impact factor: 2.046

5.  Identification of a monoclonal antibody reactive with the bovine orthologue of CD3 (BoCD3).

Authors:  W C Davis; N D MacHugh; Y H Park; M J Hamilton; C R Wyatt
Journal:  Vet Immunol Immunopathol       Date:  1993-11       Impact factor: 2.046

Review 6.  Cryptosporidiosis in animals and humans.

Authors:  S Tzipori
Journal:  Microbiol Rev       Date:  1983-03

Review 7.  Cryptosporidiosis.

Authors:  W L Current
Journal:  J Am Vet Med Assoc       Date:  1985-12-15       Impact factor: 1.936

8.  A waterborne outbreak of cryptosporidiosis in normal hosts.

Authors:  R G D'Antonio; R E Winn; J P Taylor; T L Gustafson; W L Current; M M Rhodes; G W Gary; R A Zajac
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

9.  Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines.

Authors:  J H Schiller; G Bittner; B Storer; J K Willson
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

10.  Susceptibility of major histocompatibility complex (MHC) class I- and MHC class II-deficient mice to Cryptosporidium parvum infection.

Authors:  S A Aguirre; P H Mason; L E Perryman
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more
  7 in total

1.  Role of tumor necrosis factor alpha in development of immunity against Cryptosporidium parvum infection.

Authors:  I-Sarah Lean; Sonia Lacroix-Lamandé; Fabrice Laurent; Vincent McDonald
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  An early intestinal mucosal source of gamma interferon is associated with resistance to and control of Cryptosporidium parvum infection in mice.

Authors:  Brett A Leav; Masaru Yoshida; Kathleen Rogers; Seth Cohen; Nihal Godiwala; Richard S Blumberg; Honorine Ward
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Reactive nitrogen and oxygen species ameliorate experimental cryptosporidiosis in the neonatal BALB/c mouse model.

Authors:  G J Leitch; Q He
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Localization of alpha/beta and gamma/delta T lymphocytes in Cryptosporidium parvum-infected tissues in naive and immune calves.

Authors:  M S Abrahamsen; C A Lancto; B Walcheck; W Layton; M A Jutila
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

5.  TLR4 promotes Cryptosporidium parvum clearance in a mouse model of biliary cryptosporidiosis.

Authors:  Steven P O'Hara; Pamela S Tietz Bogert; Christy E Trussoni; Xianming Chen; Nicholas F LaRusso
Journal:  J Parasitol       Date:  2011-03-23       Impact factor: 1.276

6.  The early intestinal immune response in experimental neonatal ovine cryptosporidiosis is characterized by an increased frequency of perforin expressing NCR1(+) NK cells and by NCR1(-) CD8(+) cell recruitment.

Authors:  Line Olsen; Caroline Piercey Åkesson; Anne K Storset; Sonia Lacroix-Lamandé; Preben Boysen; Coralie Metton; Timothy Connelley; Arild Espenes; Fabrice Laurent; Françoise Drouet
Journal:  Vet Res       Date:  2015-03-11       Impact factor: 3.683

7.  Pathogenicity of Cryptosporidium parvum--evaluation of an animal infection model.

Authors:  H L Enemark; V Bille-Hansen; P Lind; P M H Heegaard; H Vigre; P Ahrens; S M Thamsborg
Journal:  Vet Parasitol       Date:  2003-04-02       Impact factor: 2.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.